MDSpire - Summary
From the Journals
Commentary & Perspectives

The New Path to ADCs

Engineering payload selectivity for a better quality of life

  • March 24, 2026

  • 11 min

Share

The World ADC London panel, featuring experts like Mohit Trikha and Bob Lutz, discussed the evolution of Antibody-Drug Conjugates (ADCs) focusing on enhancing patient tolerability and quality of life. The conversation emphasized that rather than solely improving potency, the industry must prioritize the management of adverse effects due to ADC treatments. Innovative payload designs, effective linkers, and patient-centered approaches could revolutionize ADC therapies by using selectivity to better target cancers while minimizing associated toxicities, ultimately allowing patients to live more comfortably.

Original Source(s)

The New Path to ADCs

  • March 24, 2026

Related Content

Reducing the Impact of Climate-Induced Events on Patients and Oncology Staff

Although 2023 made headlines as the hottest year in human history,1 drawing the world closer to breaching the goals outlined in the Paris Agreement to substantially reduce global greenhouse gas emissi...

Awareness of Alcohol-Cancer Link Holds Steady Despite Omission in New U.S. Dietary Guidelines, Survey Finds

“The Surgeon General’s finding that alcohol consumption raises cancer risk gained attention. A clear, strong statement in the dietary guidelines could have amplified that impact—and helped to save liv...

New Tool Sharpens Leukemia Workup

Optical genome mapping increases variant detection and refines diagnosis and risk stratification

  • March 24, 2026

  • 3 min